Abstract
Tigecycline is a novel antimicrobial agent for parenteral use encompassing a broad spectrum of bacterial pathogens, including multi-resistant organisms. Here, we report the results of the first nationwide surveillance trial that was conducted in order to evaluate the susceptibility of bacterial isolates to tigecycline in a European country prior to its clinical use. A total of 2,610 Gram-positive and Gram-negative organisms recovered from hospitalized patients were tested. Minimum inhibitory concentrations (MICs) were determined using the microdilution method. All enterococci, staphylococci (including methicillin-resistant Staphylococcus aureus; MRSA), and streptococci tested were tigecycline-susceptible, except one isolate of Staphylococcus haemolyticus. Among the Gram-negative bacteria, 100% of the Escherichia coli isolates (including extended spectrum β-lactamase [ESBL]-producers) were tigecycline-susceptible, while about 10% of the Enterobacter cloacae and Klebsiella pneumoniae isolates were resistant. Based on the results of this surveillance study, tigecycline may represent a suitable option most notably for the empiric treatment of bacterial mixed infections, including in clinical situations in which multi-resistant organisms are suspected.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kresken M, Hafner D (1999) Drug resistance among clinical isolates of frequently encountered bacterial species in central Europe during 1975–1995. Study Group Bacterial Resistance of the Paul-Ehrlich-Society for Chemotherapy. Infection 27(Suppl 2):S2–S8. doi:10.1007/BF02561661
Kresken M, Hafner D, Schmitz F-J, Wichelhaus TA; Studiengruppe (2006) Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Antibiotika in Deutschland und im mitteleuropäischen Raum. Bericht über die Ergebnisse einer multizentrischen Studie der Arbeitsgemeinschaft Empfindlichkeitsprüfungen & Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e. V. aus dem Jahre 2004. Antiinfectives Intelligence, Rheinbach, Germany. Available online at: http://www.p-e-g.org/ag_resistenz/PEG-Resistenzstudie%202004.pdf
Kresken M, Hafner D, Schmitz F-J, Wichelhaus TA; Studiengruppe (2006) Resistenz bei häufig isolierten Enterobacteriaceae gegenüber Breitspektrum-Antibiotika. Chemother J 15:179–190
Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT (1999) In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 43:738–744
Fluit AC, Florijn A, Verhoef J, Milatovic D (2005) Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline. Antimicrob Agents Chemother 49:1636–1638. doi:10.1128/AAC.49.4.1636-1638.2005
Normenausschuss Medizin (NaMed) im DIN Deutsches Institut für Normung e V. (2004) Empfindlichkeitsprüfung von Krankheitserregern gegen Chemotherapeutika (DIN 58940). In: DIN Deutsches Institut für Normung e.V. (ed) DIN-Taschenbuch 222, Medizinische Mikrobiologie, Diagnostische Verfahren, 4th edn. Beuth, Berlin, Wien, Zürich
The European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee (2006) EUCAST technical note on tigecycline. Clin Microbiol Infect 12:1147–1149. doi:10.1111/j.1469-0691.2006.01578.x
The European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2008) Clinical breakpoints. European Society for Clinical Microbiology and Infectious Diseases. Available online at: http://www.srga.org/eucastwt/MICTAB/index.html
Clinical and Laboratory Standards Institute (CLSI) (2008) Performance standards for antimicrobial susceptibility testing; 18th informational supplement. M100-S18. CLSI, Wayne, PA
Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ; Tigecycline Evaluation and Surveillance Trial (TEST Program) Group (2005) In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 52:215–227. doi:10.1016/j.diagmicrobio.2005.06.001
Waites KB, Duffy LB, Dowzicky MJ (2006) Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob Agents Chemother 50:3479–3484. doi:10.1128/AAC.00210-06
Werner G, Gfrörer S, Fleige C, Witte W, Klare I (2008) Tigecycline-resistant Enterococcus faecalis strain isolated from a German intensive care unit patient. J Antimicrob Chemother 61:1182–1183. doi:10.1093/jac/dkn065
The European Antimicrobial Resistance Surveillance System (EARSS) (2006) EARSS annual report 2005. EARSS, Bilthoven, The Netherlands. Available online at: http://www.rivm.nl/earss/Images/EARSS%202005_tcm61-34899.pdf
Bradford PA, Weaver-Sands DT, Petersen PJ (2005) In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 41(Suppl 5):S315–S332. doi:10.1086/431673
Woodford N, Hill RLR, Livermore DM (2007) In vitro activity of tigecycline against carbapenem-susceptible and -resistant isolates of Klebsiella spp. and Enterobacter spp. J Antimicrob Chemother 59:582–583. doi:10.1093/jac/dkl514
Wyeth Pharmaceuticals Inc. (2005) Tygacil product insert. Wyeth Pharmaceuticals Inc., Philadelphia, PA. Available online at: http://www.fda.gov/cder/foi/label/2005/021821lbl.pdf
Livermore DM (2005) Tigecycline: what is it, and where should it be used? J Antimicrob Chemother 56:611–614. doi:10.1093/jac/dki291
Acknowledgments
We thank the following investigators who also contributed to this study by providing clinical isolates: W. R. Heizmann (Center for Medical Microbiology and Hygiene, Berlin), G. Marklein (University Hospital of Bonn), F.-J. Schmitz (Hospital of Minden, Mühlenkreiskliniken), W. Pfister and E. Straube (University Hospital of Jena), R. R. Reinert (University Hospital of Aachen), B. Grabein (Ludwig-Maximilians-Universität, Munich), R. Mutters (University Hospital of Marburg), S. Schubert and U. Ullmann (University Hospital of Schleswig-Holstein, Campus Kiel), A. Anders and S. Gatermann (University of Bochum), B. Lindner (Community Hospital Sankt Georg, Leipzig), N. Lehn (†) and H.-J. Linde (University of Regensburg).
The results of the study were presented, in part, at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, September 2006, and the 25th International Congress of Chemotherapy/17th European Congress of Clinical Microbiology and Infectious Diseases, Munich, Germany, April 2007.
This study was supported by a grant from Wyeth Pharma GmbH, Germany.
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
Members of the G-TEST Study Group are listed in the Acknowledgments section.
Rights and permissions
About this article
Cite this article
Kresken, M., Leitner, E., Brauers, J. et al. Susceptibility of common aerobic pathogens to tigecycline: results of a surveillance study in Germany. Eur J Clin Microbiol Infect Dis 28, 83–90 (2009). https://doi.org/10.1007/s10096-008-0589-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-008-0589-0